Astragalin Suppresses Colorectal Carcinogenesis by Targeting Proliferation, Oxidative Stress, and Inflammation Authors: Suhayla Hamad Shareef, Haween Toufiq Nanakaly, Salam Adil Ahmed, Noor Ali Gheni, Derin Nabaz Fisal, Nabaz Fisal Shakir Agha, Mahmood Ameen Abdulla Published: 2026 ABSTRACT AbstractBackgroundColorectal cancer (CRC) is a leading cause of cancer-related death worldwide. This study evaluated astragalin’s (AST) anti-proliferative and chemopreventive effects on CRC.MethodsAST’s effects were assessed in vitro on Caco-2 and HT-29 cells and in vivo on azoxymethane (AOM)-induced aberrant crypt foci (ACF) in rats. Rats received AST (50 or 100 mg/kg, 60 days) or 5-fluorouracil (5-FU) (35 mg/kg, 5 days).ResultsAST inhibited Caco-2 and HT-29 cell growth (IC50: 20.15–34.50 µg/mL). In AOM-induced rats, AST reduced ACF formation, improved colon histology, downregulated β-catenin, and upregulated Bax. AST also enhanced superoxide dismutase (SOD) and catalase (CAT) activities, reduced malondialdehyde (MDA) levels, and modulated tumor necrosis factor alpha (TNF-α), interlukin-6 (IL-6), and IL-10 levels.ConclusionAST demonstrated chemopreventive activity against CRC by exerting antiproliferative, antioxidant, and anti-inflammatory effects, supporting its potential as a therapeutic agent.Keywords: astragalin, colon cancer, ACF, β-catenin, bax, inflammatory cytokines, Caco-2, HT-29, AOM Introduction Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies worldwide and remains a major contributor to cancer-related morbidity and mortality. It ranks among the three most common cancers and continues to contribute significantly to cancer deaths. According to recent data from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), approximately 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally in 2022. Epidemiological projections indicate that nearly one in five individuals will develop cancer during their lifetime,1–4 while about one in nine men and one in twelve women will die from the disease.5 Furthermore, data from the American Cancer Society identify CRC as the second leading cause of cancer-related mortality in the United States.6 In 2024, an estimated 2,001,139 new cancer cases were diagnosed in the United States, resulting in approximately 611,720 cancer-related deaths.7 Cancer is characterized by uncontrolled proliferation of abnormal cells that can arise in nearly any tissue or organ when normal regulatory mechanisms fail. A tumor typically becomes clinically detectable only after reaching roughly 1 cm in diameter or containing about one million cells, at which stage it may be described as a mass, growth, tumor, nodule, or lesion.8 The development of CRC is a multistep and complex process driven by the gradual accumulation of genetic and epigenetic alterations that affect genes controlling cell proliferation, differentiation, and apoptosis. Mutations in critical oncogenes and tumor suppressor genes, including APC, KRAS, and TP53, play pivotal roles in transforming normal colonic epithelial cells into malignant tumors. These molecular changes often occur through pathways involving chromosomal instability, microsatellite instability, and epigenetic modifications. A detailed understanding of these mechanisms is essential for improving early detection and developing effective preventive and therapeutic strategies for CRC.1,2 Azoxymethane (AOM) is a potent chemical carcinogen widely used to induce CRC in experimental models.9 After administration, AOM is metabolized to active intermediates, including 1,2-dimethylhydrazine (DMH),10 which mediate DNA alkylation and induce genetic mutations. These mutations trigger the formation of aberrant crypt foci (ACF), early preneoplastic lesions in the colon, and promote apoptosis in colon epithelial cells, recapitulating the early stages of colorectal carcinogenesis.11,12 5-Fluorouracil (5-FU) is a widely used chemotherapeutic agent that effectively targets various cancers by disrupting DNA replication.13 Its mechanism of action involves inhibition of thymidylate synthase, leading to cell death. However, 5-FU’s clinical utility is often hindered by its severe gastrointestinal side effects. Moreover, it increases the levels of reactive oxygen species (ROS) and reduces the antioxidant capacity, contributing to its cytotoxic effects.14 Unfortunately, 5-FU’s lack of specificity means it also affects healthy cells, leading to toxicity. The liver metabolizes 5-FU and produces toxic byproducts, which can cause liver damage. The resulting oxidative stress and inflammation contribute to 5-FU’s harmful effects.15 Intravenous administration is common, and research suggests that oral formulations with controlled release may reduce side effects.16 To improve treatment outcomes, scientists have developed controlled drug delivery systems using polymeric materials that can minimize side effects and toxicity, while maintaining therapeutic efficacy.17 These innovative systems offer advantages over traditional dosage forms,18 including a reduced dosing frequency and sustained therapeutic effects. Numerous investigators have utilized 5-FU as a reference therapy against AOM-induced ACF in rats, as reported by several studies.19–21 However, there remains an urgent need to identify more effective and safer therapeutic strategies for the prevention and treatment of CRC. Therefore, considerable attention has recently been directed toward exploring novel bioactive compounds with potential chemopreventive properties, such as Astragalin. Astragalin (AST) (kaempferol-3-O-β-D-glucopyranoside)) is an lively usual flavonoid constituent removed from countless traditional medicine plants,22 owns different biological accomplishments and important therapeutic worth, comprising antiviral, analgesic, antibacterial, anti-allergic, anti-hepatotoxic, anti-cancer, antioxidant, anti-ulcer, and anti-inflammatory possessions.23 Wuziyanzong Pill (WZYZP) is a well-known traditional Chinese medicine frequently used to treat male reproductive dysfunction in clinical treatments.24 AST, one of the chief components of WZYZP,23 has been shown to decrease lipopolysaccharide-induced lung damage in rats by improving Nrf2 action.25 Previous studies have revealed that AST can significantly recover spermatogenesis in cyclophosphamide-induced Oligoasthenospermia mice.26 A schoolwork has established that AST can advance spermatogenesis in streptozotocin-induced diabetic mice by impeding oxidative pressure.27 In terms of antioxidant activity, AST improves the activity of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), decreases ROS buildup, and decreases oxidative stress-induced cellular injury.28 AST reduces the initiation of inflammation-related gesturing pathways and release of inflammatory intermediaries.29 In terms of anti-apoptotic properties, AST decreased the number of apoptotic cells in cardiomyocyte apoptosis mockups.17 Many studies have reported the chemoprotective effects of medicinal plants or their active constituents against AOM-induced ACF in rats has been reported by huge academics.19–21 Therefore, the present study aimed to evaluate the chemopreventive potential of AST against CRC using both in vivo and in vitro models. The in vivo study assessed the effects of AST in an AOM-induced rat model, while the in vitro study examined its antiproliferative activity in CRC cell lines Materials and Methods Ethic Approval for the Animal Experiment The research was conducted in accordance with the ARRIVE guidelines and the guidelines established by the Iraqi Animal Rights and National Scientific Recommendations for Laboratory Animal experiments.30 The animal procedures were approved by the Research Ethics Committee of Cihan University-Erbil Kurdistan Region/Iraq (approval ID number: ERB 89/07/10/2024/MAA). Normal Human Dermal Fibroblasts (NHDF) In vitro experiments, we used NHDF because these types of cells are already available in our lab, and we found that these cell lines have been used by other researchers in vitro.31,32 Cell Culture and in vitro Cytotoxicity Assays Human colorectal adenocarcinoma cell lines (Caco-2 and HT-29) and normal human dermal fibroblasts (HDF-a) were used for the in vitro cytotoxicity experiments. The inclusion of HDF-a cells as a non-malignant human cell model allowed assessment of the potential cytotoxicity and safety profile of the tested extract toward normal cells, as well as evaluation of treatment selectivity by comparing effects on normal versus cancer cells. Doxorubicin (Dox) was used as a standard anticancer drug for comparison. The Caco-2 and HT-29 cells were obtained from the American Type Culture Collection (ATCC, USA). HT-29 cells (ATCC HTB-38™) were cultured in RPMI-1640 medium (Sigma, UK), while HDF-a cells were purchased from ScienCell Research Laboratories (CA, USA) and maintained in fibroblast growth medium following the supplier’s instructions. Culture media were supplemented with 5–10% fetal bovine serum (FBS), 100 mg/mL streptomycin, and 100 IU/mL penicillin (iDNA, South America). Cells were seeded at a density of 1 × 106 cells per mL of growth medium and maintained in a humidified incubator at 37 °C with 5% CO2. All cells were allowed to reach 80–90% confluence before treatment to ensure optimal conditions for cytotoxicity testing. This standardized cell density and confluence provided reproducible and reliable results for evaluating both the anticancer efficacy of the tested extract and its selectivity toward normal cells. MTT Essay The cancer cells were detached from the cell bowl using trypsin-EDTA and centrifuged at 220 × g for 5 min. The cancer cells were resuspended, and cell compactness was assessed. A 96-well plate containing 100 µL of growth medium was used to seed tumor cells. The following day, 20 µL of various concentrations of AST were added to each well, whereas and 10% v/v DMSO was added as a blank. Forty-eight hours after AST, 10 µL of MTT (3- (4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) solution was added to the wells and incubated the incubator (4 h). The growing medium was removed, DMSO (100 µL) was added to solubilize the formazan crystals, and the permeability of the solution was evaluated at 595 nm.33 Chemicals All chemicals were obtained from (Sigma-Aldrich. Switzerland). AOM (100 mg vial) is a strong cancer-causing agent used to produce ACF in the rat colon and rectum. AOM was dissolved in 10 mL sterile buffered saline and injected subcutaneously into rats at a dose of 15 mg/kg on one occasion for two calendar weeks.21 5-FU, a usual orientation medicine, was liquefied in sterile buffered saline before intraperitoneal inoculation of rats at a dosage of 35 mg/kg for 4 weeks.34 Astragalin (AST; chemical formula C21H20O11, molecular weight 448.38, purity ≥98%) (Figure 1) was purchased from Beijing Bailingwei Technology Co., Ltd. (Beijing, China). AST was dissolved in 10% Tween-20 and administered orally to rats by gavage at doses of 50 mg/kg and 100 mg/kg body weight for a period of two months. Chemical structure of Astragalin (C21H20O11). Acute Toxicity Study Healthy adult female Sprague Dawley (SD) rats (6–8 weeks old, weighing 170–180 g) were obtained from the Animal House Unit, Cihan University-Erbil. The animals were kept under controlled conditions of humidity (50–60%), lighting (12-h light/dark cycle), temperature (22–24 °C), and provided with standard food pellets and tap water ad libitum, individually caged in a wide-mesh wire bottom type to prevent coprophagia. The acute toxicity investigation was conducted in female SD rats by the “fix dose” technique of the Organization for Economic Co-operation and Development (OECD), 2002. Guideline No.420. The recommended initial dose for the fixed-dosage approach is 500 mg/kg body weight. Rats abstained from food immediately following the oral administration of AST (dissolved in 10% Tween 20 solution) at a dose of 500 mg/kg. The rats were continuously monitored every 30 min for 3 h for general behavior, nervous system function, and autonomic signs. This observation continued for the subsequent 3 h, and any mortality was recorded for up to 24 h and then again for 14 days.35 The rats were fasted overnight on day14th and sacrifice on day 15th by intramuscular injection of ketamine (30 mg/kg, 100 mg/mL) and xylazine (3 mg/kg, 100 mg/mL).19 Blood was collected via intracardiac puncture for the liver and kidney function tests. All the rats were sacrificed by cervical dislocation. Histopathology of the liver and kidney was stained with H&E and analyzed for structural changes.36 Selection of Doses To assess its efficacy against colon cancer, two doses were chosen using a method wherein one dose was approximately one-tenth of the maximum dose tested during acute toxicity testing (50 mg/kg), whereas the other dose was twice the one-tenth dose (100 mg/kg). Experimental Design and Animals’ Treatments Healthy pathogen-free male SD rats weighing 170–180 g was obtained from the Investigational Animal Unit, Science College, Cihan University, Erbil. The rats were individually housed in separate cages. The animals were maintained on a standard diet and tap water ad libitum under controlled conditions of humidity (50–60%), lighting (12-h light/dark cycle), and temperature (22–24 °C), and they were weighed weekly. Thirty adult male rats were randomly separated into five groups of six rats each, which were reserved in separate wire-bottomed cages. The rats were provided normal pelleted food. Group 1 (normal group) rats fed by mouth 10% Tween 20 daily and injected subcutaneously with normal saline once per week for two consecutive weeks.37 Group 2 (cancer control group) rats fed with 10% Tween 20 and injected subcutaneously with 15 mg/kg AOM once per week for two consecutive weeks. Group 3 (reference group) rats received subcutaneous injections of 15 mg/kg AOM once per week for two consecutive weeks, followed by intra-peritoneal injections of 35 mg/kg 5-Fu for four weeks. Groups 4 and 5 (AST groups) received subcutaneous injections of 15 mg/kg AOM once per week for two consecutive weeks and oral administration of AST at doses of 50 mg/kg and 100 mg/kg daily for 8 weeks, respectively.20 During the experiments, the whole-body mass of the rats was measured once a week for eight weeks. At the end of 2 months, the rats were fasted overnight and sacrificed under universal anesthesia with ketamine (30 mg/kg, 100 mg/mL) and xylazine (3 mg/kg, 100 mg/mL).19,21 Blood specimens were collected by intracardiac puncture, and the serum was separated for antioxidant and proinflammatory cytokine estimation. Colons cleaned ice-cold phosphate-buffered saline (PBS) slit open lengthwise and then fixed flat amid sheets filter papers in 10% formalin for 30 minutes at 4°C.38 Macroscopically Assessment of ACF in the Colon The colon tissue was divided into proximal, intermediate, and distal regions, all equidistant from each other. The tissues were then stained with a 0.2% methylene blue stain for a duration of 10 min. The tissue was placed on a microscope slide with the mucosal surface facing upward and was observed at a magnification of 10x.20 The total number of ACF throughout the entire colon, from the distal to proximal parts, was calculated in 2-cm slices. ACF were distinguished from neighboring crypts by their enlarged size, increased density from the lamina to the basal cell layers, and clearly visible peri-cryptal regions. The parameter used to assess ACF was the mean number of ACF observed in each group. ACF diversity was quantified as the number of crypts within each focus, ranged from one to four aberrant crypts/foci. A fine blade was used under a compound microscope to isolate ACF from adjacent normal crypts.21 Histological Investigation Colon tissue was divided into 2×2 cm squares and fixed in 10% phosphate buffer formalin overnight to fix for histological. The colons were handled using an automated paraffin tissue processing machine and implanted in paraffin. The muscular epithelium was sliced into 5 µm-thick slices. The slices were then stained with hematoxylin and eosin. Each ACF was assessed for histopathology, specifically examining crypt architecture and nuclear features by comparing them to adjacent normal crypts.21 Immunochemical Staining Colon’s specimens were fixed using a 10% PBF solution and subsequently processed using an automated paraffin processing machine. Paraffin wax was used to implant the colon tissues. The Slices with a thickness of 5 µm were placed on poly-L-lysine slides and heated in an oven at a temperature of 60 °C for a duration of 2 h. The slices were deparaffinized using xylene, hydrated, and subjected to antigen retrieval by immersing them in a 10 mM citrate buffer (pH 6.0) and heating them in a microwave oven at a temperature of 90–95 °C for 20 min. Immunostaining was performed according to the manufacturer’s instructions. In brief, the endogenic peroxidase enzyme was rendered inactive by administering a solution of 0.03% H2O2 for a duration for 5 min. The colon slices were gently washed with washing buffer solution and then incubated with biotinylated primary antibodies against β-catenin (1:200) and Bax (1:100) for 15 min.39 The sections were gently washed with washing buffer and placed in a humidified chamber immersed in buffer. Subsequently, the sections were incubated with 100 µL of streptavidin–HRP solution (1:1000 dilution) for 30 minutes at room temperature. The slices were incubated with diaminobenzidine substrate chromogen for more than 7 min to achieve shadowed rinses. After thorough rinsing, counterstaining with hematoxylin was performed for 5 s. The slices were immersed in a weak ammonia solution (0.037 M/L) ten times, and the coverslips were washed. The tissue sections were examined under a compound microscope, and staining was evaluated in a blinded manner by an experienced observer to minimize bias. A semi-quantitative scoring system was applied to assess antigen expression, with positive staining indicated by a brown chromogenic signal within the cells. Staining intensity was scored on a 0–3 scale (0 = no signal, 1 = weak, 2 = moderate, 3 = strong), and the percentage of positively stained cells was recorded. A composite score, calculated by multiplying intensity by percentage of positive cells, was used to provide an objective, reproducible measure of antigen expression.38 Estimation Superoxide Dismutase (SOD)and Catalase (CAT) in Colon Tissue Homogenate The colon specimens were washed and homogenized in ice-cold phosphate-buffered saline (10%) using a Teflon homogenizer (Polytron; Heidolph Instruments GmbH and Co., KG, Schwabach, Germany). The homogenates were centrifuged at 10000 × g for 10 minutes at 4 °C, and the resulting supernatants were collected for analysis.40,41 Enzymatic activities of endogenous antioxidants were measured using commercial assay kits according to the manufacturers’ protocols. CAT activity was determined using the Cayman Chemical Company kit (cat. #707002, Ann Arbor, MI, USA), and SOD activity was measured with the Cayman Chemical Company kit (cat. #706002, Ann Arbor, MI, USA). Assays were conducted at 4 °C, and readings were performed on a microplate reader to ensure reproducibility. Estimation of Malondialdehyde (MDA) Level in Colon Tissue Homogenate To determine the quantity of malondialdehyde (MDA) in colon homogenates, a commercial thiobarbituric acid reactive substances (TBARS) assay kit was used according to the manufacturer’s instructions (Cayman Chemical Company, cat. #10009055, Ann Arbor, MI, USA).42,43 Cytokine Measurement Serum levels of TNF-α, IL-6, and IL-10 were measured using a rat cytokine multiplex kit (Millipore). Cytokines were quantified using a Luminex system (Austin, TX, USA).44,45 Statistical Analysis Statistical analysis was conducted using one-way analysis of variance (ANOVA) followed by post-hoc testing with Bonferroni’s multiple comparison analysis. All values are presented as mean ± SEM, with significance considered at p < 0.05. Results In vitro Anticancer Effects The antiproliferative effects of AST on the cancer cells are shown in Table 1. The results showed significant anti-proliferative effects of AST against selected colorectal adenosarcomas (Caco-2 and HT-29) and NDHF. The anticancer activity (IC50 values) of AST ranged between 20.15–34.50 µg/mL against Caco-2 and HT-29 cells respectively. The anticancer (IC50) value of AST in NHDF was statistically higher (IC50:168.25 µg/mL) than that in the two colorectal cell lines. This indicates that AST has a significantly lower cytotoxic effect on normal dermal human fibroblasts than on cancer cells. This outcome provides strong evidence for the inhibitory effects of AST on Caco-2 and HT-29 CRC cells. Table 1Anticancer Activity IC50 (μg/mL) of AST on Caco-2, HT-29, and NHDF After 24 h of TreatmentCellsIC50 Values (μg/mL)AstragalinDOXCaco-220.15 + 0.55a0.78 + 0.33 aHT-2934.50 + 1.13b0.60 + 0.25 aNHDF168.25 + 2.77c1.15 + 0.17 bNotes: Caco-2 and HT-29 cells and two human colorectal adenocarcinoma cell lines NHDF: normal dermal fibroblasts. Mean value ± SD of IC50 (μg/mL), inhibition concentration at which 50%. Different superscript letters indicate significance at p < 0.05.Abbreviation: DOX; Doxorubicin. Anticancer Activity IC50 (μg/mL) of AST on Caco-2, HT-29, and NHDF After 24 h of Treatment Notes: Caco-2 and HT-29 cells and two human colorectal adenocarcinoma cell lines NHDF: normal dermal fibroblasts. Mean value ± SD of IC50 (μg/mL), inhibition concentration at which 50%. Different superscript letters indicate significance at p < 0.05. Abbreviation: DOX; Doxorubicin. Acute Toxicity The acute toxicity studies did not reveal any significant adverse effects. Histological examination revealed no evidence of liver or renal damage (Figure 2). In addition, blood biochemistry analysis appeared to be within the normal parameters of the liver and kidney function tests in female rats (Tables 2 and 3). Histologic slices liver and kidney acute toxicity trial. Rats’ gavage 5 mL/kg vehicle (10% Tween 20) (A and B). Rats’ gavage 500 mg/kg of AST (C and D). No substantial alterations in constructions liver and kidney among treated and control groups (Hematoxylin and eosin stain, magnification 40x). Table 2Effects of AST on Liver Biochemical Parameters in Female RatsAnimal GroupsTotal protein (g/L)Albumin (g/L)Globulin (g/L)TB (μmol/L)ALP (IU/L)ALT (IU/L)AST (IU/L)10% Tween 2057.67±0.2113.33±0.2145.00±0.253.0±0.2589.50±0.2255.17±0.60181.3±0.21AST 500 mg/kg57.0±0.2514.0±0.2545.83±0.303.25±0.0490.50±0.4255.50±0.42182.3±0.22Notes: Data are expressed as mean ±S.E.M. There were no statistically significant differences between the groups. A similar letter within the same column indicates no significant difference (p<0.05). Effects of AST on Liver Biochemical Parameters in Female Rats Notes: Data are expressed as mean ±S.E.M. There were no statistically significant differences between the groups. A similar letter within the same column indicates no significant difference (p<0.05). Table 3Effects of AST on Renal Function Test Female Rats in Acute Toxicity StudiesAnimal GroupsSodium (mmol/L)Potassium (mmol/L)Chloride (mmol/L)CO2 (mmol/L)Urea (mmol/L)Creatinine (μmol/L)10% Tween 20147.2±0.605.0±0.36112.7±0.3314.17±0.607.16±0.4029.17±0.60AST 500 mg/kg148.2±0.605.58±0.20114.2±0.6014.17±0.607.63±0.2028.0±0.36Notes: Data are expressed as mean ±S.E.M. There were no statistically significant differences between the groups. A similar letter within the same column indicates no significant difference (p<0.05). Effects of AST on Renal Function Test Female Rats in Acute Toxicity Studies Notes: Data are expressed as mean ±S.E.M. There were no statistically significant differences between the groups. A similar letter within the same column indicates no significant difference (p<0.05). Body Weight The body masses of all rats were recorded at the beginning of the experiment and subsequently measured weekly for a period of two months. There were no significant differences in body mass between groups (Table 4). Table 4Effects of AST on the Rat’s Body Weight in AOM-Induced Colon Cancer StudyAnimal GroupsWeek 1 (g)Week 8 (g)Normal control (10% Tween 20)175.2±0.94365.2±0.94AOM control174.7±1.05340.8±33.17Reference control (35 mg/kg 5-FU)176.3±1.05367.3±0.88AST 50 mg/kg175.7±0.98385.2±0.94AST 100 mg/kg176.0±0.85365.5±16.12Notes: Values are expressed as the mean ± S.E.M. There were no statistically significant differences between the measurements of the different groups. Statistical significance was set at p< 0.05. Effects of AST on the Rat’s Body Weight in AOM-Induced Colon Cancer Study Notes: Values are expressed as the mean ± S.E.M. There were no statistically significant differences between the measurements of the different groups. Statistical significance was set at p< 0.05. Macroscopically Findings and Numeration of ACF ACF was visualized using methylene blue staining (0.2%) (Figure 3). ACF were predominantly observed in the central colon and the total number of ACF per focus was calculated (Table 5). AOM control rats exhibited macroscopically distinguishable ACF in their colonic mucosa. No ACF was detected by methylene blue staining of the entire colon of normal rats (Figure 3). The variability of ACF, considered precursor lesions to colon tumors, significantly increased in the AOM group compared with that in the AST-fed groups. Effects of AST on gross appearance of AOM-induced ACF in rat’s colon tissue. (A) Normal control: intact crypts. (B) AOM: increased ACF (Orange arrow). (C) 5-FU + AOM: reduced ACF. (D) 50 mg/kg AST + AOM: decreased crypts per ACF. (E) 100 mg/kg AST + AOM: further reduction in crypts per ACF. (0.2% Methylene blue stain, Magnification 4×). Table 5Repressive Influences of AST on AOM-Induced Diversity of ACF in Rat’s ColonAnimals GroupNumber of Crypts per ACFTotalInhibition %One CryptTwo CryptsThree CryptsFour or ≥ CryptsNormal Control000000AOM Control54.83±2.30 b47.17±2.49 b53.83±3.31b27.33±1.30 c183.16 c05-FU Control10.67±0.49a12.0±0.57 a9.16±0.60 a5.50±0.42 a37.337 a79.615 aAST 50 mg/kg14.17±0.60 a16.83±0.79 a12.83±0.83 a10.67±0.66 b54.50 b70.244 bAST 100 mg/kg10.83±0.60 a12.50±0.76 a11.33±0.55 a8.16±0.47 a42.82 a76.621 aNotes: Data are shown as mean ± standard error of the mean (n=6). Data with different superscript letters in the same column are significantly different (p < 0.05). ANOVA and Bonferroni’s post hoc test. Repressive Influences of AST on AOM-Induced Diversity of ACF in Rat’s Colon Notes: Data are shown as mean ± standard error of the mean (n=6). Data with different superscript letters in the same column are significantly different (p < 0.05). ANOVA and Bonferroni’s post hoc test. Histopathology Examination Histological sections of ACF were examined in a manner similar to that for muscle tissue. Colon sections from all macroscopically visible AFCs were stained with H and E stain for evaluation. The normal group showed rounded cell outlines, with nuclei positioned at the base. The AOM group exhibited moderately more ACF, displaying noticeable nuclear atypia, reduced goblet cells, decreased mucin levels, and narrow lumens. ACF appeared elongated and larger than normal crypts, with strongly stained cytoplasm. Epithelial cells within the ACF showed characteristic elongation and slight stratification of nuclei, loss of cell polarity, and increased mitosis compared to adjacent normal crypts (Figure 4). The AST-fed group exhibited reduced mitosis and cellular proliferation, as well as reduced ACF formation in the rat colon, with only minor morphological differences compared to the ACF associated with the AOM control group. Effects of AST on the histology of AOM-induced aberrant crypt foci (ACF) in rat colon. (A) Normal control group: colon mucosa showing regularly shaped crypts with basal nuclear polarization and preserved goblet cells (blue arrow). (B) AOM group: pronounced ACF with elongated and stratified nuclei, loss of basal nuclear polarization, and reduced goblet cell numbers (blue arrow). (C) 5-FU + AOM group: mild ACF with slight nuclear elongation, minor reduction in goblet cells, and partial preservation of crypt architecture (blue arrow). (D) 50 mg/kg AST + AOM group: mild ACF with slightly elongated nuclei, minimal reduction in goblet cells, and partial nuclear stratification (blue arrow). (E) 100 mg/kg AST + AOM group: ACF with near-normal crypt outline, mild nuclear elongation, partial preservation of goblet cells, and reduced nuclear stratification (blue arrow). Colon sections were cut along the longitudinal axis and stained with hematoxylin and eosin (H&E). Magnification 100×. Immunohistochemistry Results Influence of AST on β -Catenin Stain Colon in AOM-Induced ACF in Rats The chemopreventive effects of AST were assessed by immunohistochemical examination of β-catenin, which is a reliable marker of cell proliferation. AST resulted in the downregulation of β-catenin protein. Colon tissue samples from the control and AST-fed groups are shown in Figure 5. The intensity of β-catenin staining in the nuclei of colon cells was significantly stronger in AOM control rats than that in AST-fed rats. Immunohistochemical analysis of β-catenin expression in AOM-induced aberrant crypt foci (ACF) in rat colon following AST treatment. (A) Normal control: minimal basal β-catenin expression. (B) AOM group: pronounced upregulation and nuclear localization of β-catenin (Orange arrow). (C) 5-FU + AOM: marked reduction in β-catenin expression compared with AOM alone. (D) 50 mg/kg AST + AOM: moderate downregulation of β-catenin relative to AOM group. (E) 100 mg/kg AST + AOM: substantial suppression of β-catenin expression, indicating dose-dependent effects of AST (orange arrow). (Immunohistochemically β -catenin stain, Magnification 100x). AST Effect on Bax Protein Expression In the AOM control group, notably low immunostaining for Bax protein was observed in colon tissue slices (Figure 6). A significant increase in Bax protein staining was observed in the AST-fed groups. Immunohistochemical analysis of Bax expression in AOM-induced aberrant crypt foci (ACF) in rat colon following AST treatment (A) Normal control: minimal Bax expression. (B) AOM group: marked downregulation of Bax protein (blue arrow). (C) 5-FU + AOM: increased Bax expression compared with AOM group. (D) 50 mg/kg AST + AOM: moderate upregulation of Bax relative to AOM group. (E) 100 mg/kg AST + AOM: pronounced upregulation of Bax, indicating a dose-dependent effect of AST (blue arrow). (Immunohistochemically Bax stains Magnification 100 x). AST Effect on Enzymatic Antioxidants Rats that were injected with AOM and fed either AST or 5FU showed significantly enhanced activities of SOD and CAT in the colon tissue homogenate compared to the AOM control group. The AST-fed groups exhibited an increase in enzymatic activity, which facilitated their transportation to normal levels (Figure 7A and B). (A) Effect of AST on SOD activities in colon tissue homogenate. Values were expressed as mean ± SEM. *Differences were significant at the 0.05 level between groups. * For p < 0.05, **** For p < 0.0001. (B) Influence of AST on CAT activity in colon tissue homogenate Values were expressed as mean ± SEM. *Differences were significant at the 0.05 level between groups. *** For p < 0.001; **** For p < 0.0001; ns for p >0.05. (C) Consequence of AST on MDA quantity in AOM-induced ACF in rat’s colon tissue homogenate. Entirely standards are stated as mean ± SEM. Means among groups (n = 6 rate/group) show a significant difference. ns, non-significant; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. continued. continued. AST Effect on Malondialdehyde (MDA) Quantity in AOM-Induced ACF in Rats Treatment with AST reduced the level of lipid peroxidation compared to that observed in the AOM control group. Lipid peroxidation was significantly increased in the AOM group compared to that in both the normal and AST-fed groups. Feeding rats with AOM and AST significantly reduced the amount of MDA to within the normal range. Thus, when AST or 5-FU was administered, AOM toxicity was reduced (Figure 7C). AST Effect on Serum Cytokines The experimental group treated with AST showed a decrease in serum levels of TNF-α and IL-6, whereas the levels of IL-10 increased (Figure 8). Effect of AST on (A) TNF-α, (B) IL −6 and (C) IL-10 on AOM-induced Aberrant crypt foci in rats. Data are expressed as mean ± SEM. Means among groups (n = 6 rate/group) show a significant difference. ns, non-significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. Discussion Therapeutic plants and their bioactive constituents have long served as sources of traditional remedies and as foundations for modern drug development. It is estimated that nearly 60% of current anticancer drugs are derived from natural plant products.46 Numerous studies have demonstrated that herbal compounds possess significant anticancer activity, capable of targeting and inhibiting cancer cell proliferation.47 In this context, AST exhibited notable cytotoxic effects in vitro against CRC cell lines (Caco-2 and HT-29), consistent with previous reports highlighting the anticancer potential of various medicinal plant extracts and their active ingredients.48,49 Acute toxicity assessment revealed no signs of adverse effects or mortality, indicating that AST is safe when administered orally at 500 mg/kg. These findings are consistent with previous studies reporting the absence of renal, hepatic, and hematological toxicity following administration of various bioactive compounds.36,40,44,50 ACF enumeration revealed that AOM significantly increased ACF number, particularly in the middle colon, and induced morphological alterations, including elongated nuclei and reduced mucin-secreting cells.19,20,51,52 AST treatment markedly attenuated ACF formation and preserved colonic histoarchitecture, effects comparable to the 5-FU reference drug.21,53–55 The modulation of mucin secretion and crypt morphology reflects AST’s protective role against early colorectal neoplasia. These findings are consistent with previous reports and suggest that AST mitigates colon injury by maintaining epithelial structure and suppressing precancerous lesions, highlighting its potential as a chemopreventive agent.56 The current study demonstrates that AST significantly downregulates β-catenin expression in the colons of AOM-treated rats, an effect comparable to the reference drug 5-FU.11,19,38,57 β-Catenin is a central mediator of Wnt signaling, regulating epithelial integrity, proliferation, and tumor progression.58 At the membrane, β-catenin associates with E-cadherin to maintain cell-cell adhesion, restricting tumor cell migration. Loss of E-cadherin releases β-catenin into the cytoplasm, promoting nuclear translocation and activation of oncogenic target genes, including CyclinD1, c-Myc, and CD44, which drive proliferation, invasion, and metastasis.58 Nuclear β-catenin overexpression is strongly associated with poor prognosis and disease progression in CRC.59 AST also modulated apoptotic signaling through upregulation of Bax, a pro-apoptotic protein known to suppress tumor growth, while Bax deficiency is linked to enhanced cancer progression.19 By simultaneously downregulating β-catenin and enhancing Bax expression, AST appears to restore normal apoptotic pathways and inhibit aberrant cell proliferation. These molecular effects likely contribute to the observed reduction in ACF and preservation of colonic histoarchitecture, highlighting AST’s multifaceted chemopreventive action against early colorectal carcinogenesis. The present study demonstrated that AST administration significantly decreased MDA levels while enhancing SOD and CAT activities in rat colon homogenates compared with the AOM control group, consistent with previous reports.21,49,60 Similarly, treatment with 5-FU improved antioxidant enzyme activities and reduced MDA levels in colon tissues, in agreement with prior studies showing enhanced SOD and CAT activities and diminished lipid peroxidation following 5-FU administration.61 AST treatment significantly reduced proinflammatory cytokines, including TNF-α and IL-6, while increasing the anti-inflammatory cytokine IL-10, suggesting that its chemopreventive effects involve attenuation of AOM-induced inflammation.19,38 Levels of TNF-α and IL-6 were markedly higher in the AOM control group compared with AST-treated rats.21 By suppressing these proinflammatory mediators, AST may inhibit β-catenin maintenance62 and prevent ACF formation in the colon, highlighting its anti-inflammatory and antitumor potential in early colorectal carcinogenesis.34 Limitations and Future Directions This study highlights the chemopreventive potential of AST in AOM-induced colorectal ACF in rats. However, several limitations should be acknowledged. The study was conducted with a relatively small number of animals (30 rats divided into five groups) and evaluated only two AST doses (50 and 100 mg/kg), limiting the ability to define optimal therapeutic concentrations and assess dose-dependent effects. Additionally, the investigation focused solely on AOM-induced ACF, and comprehensive molecular analyses to elucidate the precise mechanisms of AST action, including its modulation of β-catenin/Wnt signaling, apoptotic pathways, oxidative stress, and inflammatory mediators, were not fully performed due to resource constraints. Future research should incorporate a wider range of AST doses and larger experimental cohorts to improve statistical power and define optimal therapeutic regimens. Mechanistic studies using advanced molecular and cellular approaches are warranted to dissect AST’s effects on key oncogenic pathways and biomarkers of CRC progression. Translational relevance can be enhanced by employing human-relevant preclinical models, including genetically engineered animals, organoids, and immunocompetent systems that recapitulate the tumor microenvironment. Incorporating advanced drug delivery strategies, such as nano-formulations (liposomes, polymeric nanoparticles, dendrimers, or micelles), could improve AST bioavailability, enable targeted delivery to colonic tissue, and minimize systemic toxicity. Additionally, integrating multi-omics analyses—including transcriptomics, proteomics, and metabolomics—may reveal predictive biomarkers, elucidate molecular mechanisms, and support the clinical development of AST as a safe and effective chemopreventive or therapeutic agent against CRC. Conclusion AST demonstrates potent chemopreventive effects against AOM-induced colorectal carcinogenesis in rats and suppresses proliferation of Caco-2 and HT-29 CRC cells in vitro. AST modulated key molecular pathways by downregulating β-catenin and upregulating Bax, enhanced antioxidant defenses (SOD, CAT), reduced lipid peroxidation (MDA), and attenuated inflammatory responses (decreased TNF-α and IL-6, increased IL-10). Histological analyses confirmed preservation of colon architecture, and acute toxicity studies indicated AST is safe at the tested doses. Collectively, these findings support AST as a promising candidate for CRC prevention and warrant further mechanistic and clinical investigations to assess its therapeutic potential.